Combination cancer therapy using biphenyl compounds and immune checkpoint molecular regulators

JP2024535407A5Inactive Publication Date: 2024-11-15TAIHO PHARMA CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024518857
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-30
Filing Date
2022-09-29
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Benefits of technology

【0015】 本開示の抗腫瘍剤によれば、副作用の発現を抑制しつつ、高い抗腫瘍効果を有するがん治療を行うことが可能となる。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention provides a novel cancer treatment method that has few side effects and exhibits an extremely excellent antitumor effect. The antitumor agent includes a biphenyl compound for use in treating a subject having cancer. The present invention provides a treatment method that includes administering an immune checkpoint molecule regulator to a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to an antitumor agent comprising a biphenyl compound or a salt thereof in combination with an immune checkpoint molecule modulator, as well as an antitumor effect enhancer and a kit preparation. [Background technology]

[0002] Lysine-specific demethylase 1 (LSD1) is an epigenetic enzyme that mono- or dimethylates the 4th lysine (H3K4) and the 9th lysine (H3K9) of histone H3 protein. In addition to its function as an epigenetic regulator, LSD1 also regulates non-histone substrates such as DNMT1, p53, STAT3, and E2F1 (Non-Patent Document 1). LSD1 is also a component of various multiprotein complexes and has been shown to be associated with various gene regulatory proteins (Non-Patent Document 2). Many studies have revealed that LSD1 plays a crucial role in several cellular processes in normal and cancer cells, such as stem cell regulation, differentiation, cell motility, and epithelial-mesenchymal transition (Non-Patent Document 3).

[0003] LSD1 is highly expressed in many cancers and is associated with poor prognosis (Non-Patent Document 4). LSD1 is involved in various stages of cancer, such as cancer development, progression, metastasis, and recurrence after treatment. In recent years, methods targeting LSD1 have been recognized as promising for cancer treatment. Clinical trials of several types of LSD1 inhibitors for cancer treatment are underway (Non-Patent Document 1).

[0004] On the other hand, the immune system is important for self-defense against various diseases caused by factors within the body. A decrease in the function of the immune system has adverse pathological effects, such as the onset of bacterial and viral infections, the development of tumors, and delayed recovery from injuries and illnesses. Therefore, activating the immune system is extremely important for the prevention and treatment of various diseases. In addition, cancer immunotherapy has been developed as a new cancer treatment method.

[0005] Activation of adaptive immune responses is initiated by the binding of antigen peptide-MHC complexes to the T cell receptor (TCR). This binding is controlled by costimulation and co-inhibition through binding between the B7 family, which is a costimulatory molecule, and the CD28 family, which is a receptor for the B7 family. In other words, two characteristic signaling events are required for T cells to be activated specifically to an antigen, and T cells that are stimulated only by antigen, without costimulation from the B7 family, become unresponsive (anergy), thereby inducing immune tolerance in T cells.

[0006] Using this mechanism, cancer cells suppress the activation of antigen-specific T cells, escape from the immune surveillance mechanism, and continue to proliferate. Therefore, in cancer treatment, it is considered effective to induce an antitumor immune response in the body of a cancer patient by enhancing costimulation and inhibiting costhibition, and to control the immune escape of tumors, and various cancer immunotherapies targeting costimulatory molecules (stimulatory costimulatory molecules) or costhibitory molecules (inhibitory costimulatory molecules) have been proposed (Patent Document 6). For example, nivolumab (an IgG4 monoclonal antibody against human PD-1) is used for malignant melanoma, etc., as an immune checkpoint molecule regulator that activates T cells by inhibiting the binding of PD-1 and its ligands (PD-L1, PD-L2) (Patent Document 1 and Non-Patent Document 5).

[0007] A biphenyl compound represented by the following formula (I), 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile, or a salt thereof, is known as an LSD1 inhibitor (Patent Document 2), and the combined use of the LSD1 inhibitor with other antitumor agents has been reported (Patent Document 3).

[0008] However, the biphenyl compound represented by formula (I) has not yet been used in combination with an immune checkpoint molecule regulator, and the immunostimulatory effect of the biphenyl compound represented by formula (I) is unknown. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] International Publication No. 2004 / 004771 [Patent Document 2] International Publication No. 2017 / 090756 [Patent Document 3] International Publication No. 2018 / 216795 [Non-patent literature]

[0010] [Non-Patent Document 1] J.Hematol.Oncol, 12:129 (2019) [Non-Patent Document 2] Cancers(Basel), 11:324 (2019) [Non-Patent Document 3] Crit.RevEukaryot.Gene Expr,22:53-59 (2012) [Non-Patent Document 4] Pharmacol.Res,164:105335 (2020) [Non-Patent Document 5] N.Engl.J.Med.,366:2443-2454 (2012) Summary of the Invention [Problem to be solved by the invention]

[0011] An object of the present disclosure is to provide a novel cancer treatment method that has few side effects and exhibits extremely excellent antitumor effects. [Means for solving the problem]

[0012] The combined use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile (hereinafter referred to as Compound A) or its salt with an immune checkpoint molecule modulator was investigated, and the antitumor effect was also investigated. As a result, it was found that the antitumor effect was more significantly enhanced without causing serious side effects compared to the use of a single agent.

[0013] Specifically, in one embodiment, the present disclosure provides the following aspects [1] to

[26] . [1] An antitumor agent for treating a subject having cancer, comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof, An anti-tumor agent, wherein the treatment comprises administering to a subject an immune checkpoint molecule modulator. [2] The antitumor agent described in [1], wherein the immune checkpoint molecule regulator is at least one selected from the group consisting of a PD-1 pathway antagonist and a CTLA-4 pathway antagonist. [3] The antitumor agent described in [1] or [2], wherein the immune checkpoint molecule regulator is a PD-1 pathway antagonist. [4] The antitumor agent according to [2] or [3], wherein the PD-1 pathway antagonist is at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody. [5] The antitumor agent described in [2] or [3], wherein the PD-1 pathway antagonist is an anti-PD-1 antibody or an anti-PD-L1 antibody. [6] The antitumor agent described in [2] or [3], wherein the PD-1 pathway antagonist is an anti-PD-1 antibody. [7] The antitumor agent described in [2], wherein the CTLA-4 pathway antagonist is an anti-CTLA-4 antibody. [8] An agent for enhancing the antitumor effect of an immune checkpoint molecule modulator, comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof as an active ingredient. [9] An antitumor agent for treating a cancer patient administered an immune checkpoint molecule modulator, comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof.

[10] An antitumor agent for treating a cancer patient administered 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof, which comprises an immune checkpoint molecule modulator.

[11] 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof for use in the treatment of a tumour in combination with an immune checkpoint molecule modulator.

[12] 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof for use in enhancing the antitumor effect of an immune checkpoint molecule modulator.

[13] 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof for use in treating a tumour in a cancer patient receiving an immune checkpoint molecule modulator.

[14] An immune checkpoint molecule modulator for use in treating a tumor in a cancer patient who has been administered 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof.

[15] A combination of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof and an immune checkpoint molecule modulator for use in treating a tumor.

[16] Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof for the manufacture of an antitumor agent to be administered in combination with an immune checkpoint molecule modulator.

[17] Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof for producing an antitumor effect enhancer for enhancing the antitumor effect of an immune checkpoint molecule modulator.

[18] Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof for the manufacture of an antitumor agent for treating a cancer patient administered an immune checkpoint molecule modulator.

[19] Use of an immune checkpoint molecule modulator for the manufacture of an antitumor agent for treating a cancer patient to which 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof has been administered.

[20] Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof and an immune checkpoint molecule modulator for the manufacture of an antitumor agent.

[21] A method for treating a tumor, comprising administering to a subject in need of tumor treatment a combination of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof and an immune checkpoint molecule modulator.

[22] A method for enhancing the anti-tumor effect of an immune checkpoint molecule modulator, comprising administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof to a subject in need of an enhanced anti-tumor effect of an immune checkpoint molecule modulator.

[23] A method for treating a tumor in a cancer patient receiving an immune checkpoint molecule modulator, comprising administering 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof to a subject in need of tumor treatment.

[24] A method for treating a tumor in a cancer patient receiving 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof, comprising administering an immune checkpoint molecule modulator to a subject in need of tumor treatment.

[25] A method for treating a tumor, comprising administering a combination of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof and an immune checkpoint molecule modulator to a subject in need of tumor treatment.

[26] A pharmaceutical composition for preventing and / or treating a tumor, comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof, and an immune checkpoint molecule modulator.

[0014] Furthermore, in other embodiments, the present disclosure includes the following aspects. An antitumor agent comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof and an immune checkpoint molecule modulator administered in combination. A method for treating cancer patients with high gMDSC levels, comprising administering to the patient an antitumor agent comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof, and / or an immune checkpoint molecule modulator, as a monotherapy or combination therapy. To predict the efficacy of chemotherapy in a cancer patient when an antitumor agent containing 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof, and / or an immune checkpoint molecule modulator is administered to the cancer patient based on the amount of granulocytic myeloid-derived suppressor cells (gMDSC) in a sample collected from the cancer patient; and A method for treating cancer, comprising administering the antitumor agent to a cancer patient for whom chemotherapy using the anticancer agent is expected to be effective. A method for predicting the effect of chemotherapy for cancer treatment, comprising predicting the effect of chemotherapy when an antitumor agent containing 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof, and / or an immune checkpoint molecule modulator is administered to a cancer patient, based on the amount of granulocytic myeloid-derived suppressor cells (gMDSC) in a sample collected from the cancer patient. Effect of the Invention

[0015] According to the antitumor agent of the present disclosure, it is possible to perform cancer treatment with high antitumor effect while suppressing the occurrence of side effects. [Brief description of the drawings]

[0016] [Figure 1A] The ratio of granulocytic myeloid-derived suppressor cells (gMDSC, equivalent to polymorphonuclear MDSC) among tumor-infiltrating leukocytes is shown. [Figure 1B] The ratio of CD8 positive T cells among tumor-infiltrating leukocytes is shown. [Figure 2A] The antitumor effect of compound A in a wild-type (immune mature) mouse model implanted with the mouse colon cancer cell line MC38 is shown. [Figure 2B] The antitumor effect of compound A in an immunodeficient mouse model implanted with the mouse colon cancer cell line MC38 is shown. [Diagram 3] The combined effect of compound A and anti-mouse PD-1 antibody is shown in a wild-type mouse model implanted with the mouse colon cancer cell line MC38. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile is represented by the following structure: [ka]

[0018] In this disclosure, the above compound is referred to as "Compound A". Compound A is described as Example Compound 37 in International Publication No. WO 2017 / 090756, the disclosure of which is incorporated herein by reference in its entirety. Compound A can be produced by a method known in the art, and the production method is not particularly limited, but can be produced by, for example, the method described in International Publication No. WO 2017 / 090756 or International Publication No. WO 2021 / 095835, the disclosure of which is incorporated herein by reference in its entirety.

[0019] The present disclosure relates to an antitumor agent (interchangeably referred to as a "tumor therapeutic agent"), an antitumor effect enhancer, and a kit formulation, which are administered in combination with compound A or a salt thereof and an immune checkpoint molecule modulator (particularly, an anti-PD-1 antibody); use thereof; a tumor treatment method; and a method for enhancing an antitumor effect.

[0020] Compound A or its salt used in the present disclosure may be in the form of crystal. The scope of Compound A or its salt includes a mixture of single crystals and polymorphic crystals. Such crystals can be produced by crystallization according to a crystallization method known in the art. Compound A or its salt may be a solvate (e.g., a hydrate) or a non-solvate. Any of these forms are included in the scope of the compound or its salt of the present disclosure.

[0021] Isotopes (e.g. 3 H, 14 C. 35 S, 125 Compound A labeled with I) is also included within the scope of Compound A or a salt thereof used in the present disclosure.

[0022] The salt of compound A used in the present disclosure refers to the salt generally used in the field of organic chemistry.Examples of such salt include the salt whose counter ion is cation and the salt whose counter ion is anion.The salt of compound A is preferably a pharmaceutically acceptable salt.

[0023] Examples of salts in which the counter ion is a cation include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts; and organic amine salts such as trimethylamine salts, triethylamine salts, dicyclohexylamine salts, ethanolamine salts, diethanolamine salts, triethanolamine salts, procaine salts, and N,N'-dibenzylethylenediamine salts.

[0024] Examples of salts in which the counter ion is an anion include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, and perchlorate; organic acid salts such as acetate, formate, maleate, fumarate, tartrate, citrate, ascorbate, benzoate, and trifluoroacetate; and sulfonate salts such as methanesulfonate, isethionate, benzenesulfonate, and p-toluenesulfonate.

[0025] An example of a salt of compound A is a benzoate salt. Other examples include a sorbate salt, a succinate salt, an L-tartrate salt, or a hydrochloride salt. Other examples include a hemifumarate salt, a monooxalate salt, a mesylate salt, an esylate salt, a maleate salt, a monofumarate salt, or a hemixalate salt.

[0026] The immune checkpoint molecule modulator disclosed herein acts directly on immune checkpoint molecules, and is therefore capable of inducing anti-tumor immune responses in vivo in cancer patients and controlling tumor immune evasion.

[0027] Examples of immune checkpoint molecule regulators include substances that promote the function of costimulatory molecules (stimulatory costimulatory molecules) or substances that inhibit the function of costimulatory molecules (inhibitory costimulatory molecules). Examples of immune checkpoint molecules include B7 family (B7-1, B7-2, PD-L1, PD-L2, etc.), CD28 family (CTLA-4, PD-1, etc.), TNF superfamily (4-1BBL, OX40L), TNF receptor superfamily (4-1BB, OX40) molecules, TIGIT pathway molecules (TIGIT, etc.), and LAG-3 pathway molecules (LAG-3, etc.). Substances that target one or more immune checkpoint molecules can be used as immune checkpoint molecule regulators. Examples of such agents include PD-1 pathway antagonists, ICOS pathway agonists, CTLA-4 pathway antagonists, CD28 pathway agonists, BTLA pathway antagonists, 4-1BB pathway agonists, TIGIT pathway antagonists, and LAG-3 pathway antagonists.

[0028] In the present disclosure, from the viewpoint of suppressing side effects, the immune checkpoint molecule modulator is preferably at least one or more selected from the group consisting of a PD-1 pathway antagonist, an ICOS pathway agonist, a CTLA-4 pathway antagonist, and a CD28 pathway agonist, more preferably at least one or more selected from the group consisting of a PD-1 pathway antagonist and a CTLA-4 pathway agonist, and even more preferably a PD-1 pathway antagonist.

[0029] PD-1 pathway antagonists inhibit immunosuppressive signals from PD-1 expressed in T cells. PD-L1 or PD-L2 is a ligand of PD-1, and examples of PD-1 pathway antagonists include anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, PD-1 extracellular domain, PD-L1 extracellular domain, PD-L2 extracellular domain, PD-1-Ig (a fusion protein of PD-1 extracellular domain and FC region of immunoglobulin (Ig)), PD-L1-Ig, PD-L2-Ig, PD-1 siRNA, PD-L1 siRNA, and PD-L2 siRNA. The PD-1 pathway antagonist is preferably an anti-PD-1 antibody, anti-PD-L1 antibody, or anti-PD-L2 antibody, more preferably an anti-PD-1 antibody or anti-PD-L1 antibody, and particularly preferably an anti-PD-1 antibody.

[0030] The CTLA-4 pathway antagonist suppresses the immunosuppressive signal from CTLA-4 expressed in T cells. Examples of CTLA-4 ligands include B7-1 (CD80) and B7-2 (CD86). The CTLA-4 pathway antagonist is preferably an anti-CTLA-4 antibody, a CTLA-4 extracellular domain, a CTLA-4-Ig, an anti-B7-1 (CD80) antibody, or an anti-B7-2 (CD86) antibody, more preferably an anti-CTLA-4 antibody or a CTLA-Ig, and particularly preferably an anti-CTLA-4 antibody.

[0031] In one embodiment, the immune checkpoint molecule modulator is preferably at least one selected from the group consisting of anti-PD-1 antibody, anti-PD-L1 antibody, and anti-CTLA-4 antibody, more preferably at least one selected from the group consisting of anti-PD-1 antibody and anti-PD-L1 antibody, and particularly preferably an anti-PD-1 antibody.

[0032] Examples of antibodies include immunoglobulins (IgA, IgD, IgE, IgG, IgM, IgY, etc.), Fab fragments, F(ab')2 fragments, single-chain antibody fragments (scFv), single-domain antibodies, and diabodies (Nat. Rev. Immunol., 6:343-357, 2006). These antibodies include monoclonal and polyclonal antibodies such as human antibodies, humanized antibodies, chimeric antibodies, mouse antibodies, llama antibodies, and chicken antibodies.

[0033] Humanized or human IgG monoclonal antibodies are preferred.

[0034] In the present disclosure, examples of anti-PD-1 antibodies include nivolumab, pembrolizumab, zimberelimab, semisumab, spartalizumab, budigalimab, camrelizumab, cetrelimab, dosta-limab, ezabenlimab, lambrolizumab, penprimab, pimivalimab, pucotenlimab, sasanlimab, sintilimab, tislelizumab, toripalimab, and the like, with nivolumab, pembrolizumab, and zimberelimab being preferred.

[0035] In the present disclosure, examples of anti-PD-L1 antibodies include atezolizumab, durvalumab, avelumab, galibrimab, lodapolimab, cosibelimab, socasolimab, etc., with atezolizumab, durvalumab, and avelumab being preferred, and atezolizumab being more preferred.

[0036] In the present disclosure, anti-CTLA-4 antibodies include ipilimumab, tremelimumab, quabonlimab, zaliflimumab, and the like, with ipilimumab being preferred.

[0037] In the present disclosure, CTLA-4-Ig includes abatacept and the like, with abatacept being preferred.

[0038] In the present disclosure, anti-TIGIT antibodies include vibostolimab, osipelimbab, donbanalimab, tiragolumab, and the like.

[0039] In the present disclosure, anti-LAG-3 antibodies include liratrimab, favezelimab, fianlimab, and the like.

[0040] These antibodies can be produced by known antibody preparation methods, and commercially available antibodies can also be used.

[0041] In the present disclosure, when two or more immune checkpoint molecule modulators are used, for example, an anti-PD-1 antibody and an anti-CTLA-4 antibody, or an anti-PD-1 antibody and an anti-LAG-3 antibody may be used in combination, or a bispecific antibody capable of binding to both PD-1 and CTLA-4, or both PD-1 and LAG-3 may be used. Examples of bispecific antibodies include XmAb20717 (PD-1×CTLA-4), tebotelimab (PD-1×LAG-3), etc.

[0042] In the present disclosure, from the viewpoint of enhancing the antitumor effect of the immune checkpoint molecule modulator by compound A, the daily dose of compound A or a salt thereof is preferably 50 to 200%, more preferably 75 to 150%, and particularly preferably 100% of the recommended dose for administration of compound A or a salt thereof alone.

[0043] A typical daily dosage of Compound A or a salt thereof may range from 100 picograms to 100 milligrams per kilogram of body weight, more typically from 10 nanograms to 25 milligrams per kilogram of body weight. More typically, a daily dose of Compound A or a salt thereof may range from 100 nanograms to 20 milligrams per kilogram of body weight, although higher or lower dosages may be used as needed. For example, a daily dosage may be from 1 microgram to 20 milligrams per kilogram of body weight, more typically from 10 micrograms to 20 milligrams per kilogram of body weight, and even more typically from 100 micrograms to 20 milligrams per kilogram of body weight.

[0044] The dosage is expressed as the amount of drug administered relative to the patient's body surface area (mg / m 2 A typical daily dose of Compound A or a salt thereof is 3700 pg / m 2 ~3700 mg / m 2 For example, a daily dose may range from 370 ng / m 2 ~925 mg / m 2 , more typically 3700 ng / m 2 ~740 mg / m 2 However, higher or lower doses may be used if necessary. For example, 37 μg / m 2 ~740 mg / m 2 , more typically 370 μg / m 2 ~740 mg / m 2 , or 3700 μg / m 2 ~740 mg / m 2 It is possible.

[0045] Compound A or a salt thereof of the present disclosure may be orally administered in a single dose ranging from, for example, 0.05 to 3000 mg. Typically, it may be in the range of 10 to 1000 mg. Typical doses include 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, and 1000 mg. The dosage can be increased or decreased stepwise from any dosage in the above range (0.05 to 3000 mg) in units of, for example, 1 mg, 5 mg, 10 mg, 20 mg, or 50 mg.

[0046] In the present disclosure, from the viewpoint of the enhancing effect of the antitumor effect of the immune checkpoint molecule modulator by compound A, the daily dose of the immune checkpoint molecule modulator is preferably 50 to 200%, more preferably 75 to 150%, and particularly preferably 100%, of the recommended dose when the immune checkpoint molecule modulator is administered alone.

[0047] Typical recommended doses of nivolumab when administered as a single agent include 2 mg / kg (body weight) or 3 mg / kg (body weight) per dose.

[0048] Typical recommended doses of pembrolizumab as a single agent include 2 mg / kg (body weight) per dose or 200 mg per dose.

[0049] A typical recommended dose of atezolizumab as a single agent is 1,200 mg per administration.

[0050] A typical recommended dose of avelumab or durvalumab as a single agent is 10 mg / kg (body weight) per dose.

[0051] A typical recommended dose of ipilimumab when administered as a single agent is 3 mg / kg (body weight) per dose.

[0052] In this specification, the "recommended dose" refers to a dose determined through clinical trials, etc., which ensures safe use without the occurrence of serious side effects, and provides the maximum therapeutic effect. Specifically, the "recommended dose" refers to a dose approved, recommended, or suggested by public institutions or corporations such as the Pharmaceuticals and Medical Devices Agency (PMDA), the Food and Drug Administration (FDA), the European Medicines Agency (EMA), etc., and is described in package inserts, questionnaires, treatment guidelines, etc., and is preferably a dose approved by a public institution selected from the group consisting of the PMDA, the FDA, and the EMA.

[0053] The administration schedule for the antitumor agent of the present disclosure can be appropriately selected depending on the type, stage, etc. of cancer.

[0054] The administration schedule of compound A or a salt thereof is not particularly limited, so long as it includes one week or two weeks of continuous administration followed by one week of drug rest. When a two-week (14-day) administration schedule including one week (7 days) of continuous administration followed by one week (7 days) of drug rest is considered as one cycle, the cycle may be performed once to treat a disease or disorder, or may be repeated two or more times. That is, it can be administered in one cycle, or more than one cycle, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more cycles, according to a specific administration schedule. In some embodiments, it can be administered in a long period consisting of multiple cycles. For example, it can be administered in a period of 6 months with about 13 to 15 cycles of treatment or administration; 1 year with about 25 or 26 cycles of treatment; or 3 years or more with about 75 to 100 cycles of treatment. In addition, when a 3-week (21-day) administration schedule with a 1-week (7-day) drug holiday period after 2-week (14-day) administration is considered as one cycle, the cycle may be repeated once or twice or more. That is, the administration schedule may be one cycle or more than one cycle, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 cycles or more. In some cases, more cycles may be administered. For example, about 10 cycles for 6 months, about 20 cycles for 1 year, about 50 to 60 cycles for 3 years, or more cycles for a longer period.

[0055] In addition, in the administration schedule of compound A, as long as the administration is continued according to a schedule that provides a one-week drug holiday after one or two weeks of continuous administration, the administration may be stopped thereafter, or administration may be resumed after a certain period of drug holiday (no administration). Furthermore, the administration schedule may include a schedule having multiple drug holidays. In one embodiment of an administration schedule having a drug holiday, it is sufficient that the condition "one week or two weeks of continuous administration followed by one week of drug holiday" is satisfied in the administration period before the drug holiday and the administration period after the drug holiday. In another embodiment of an administration schedule having two drug holidays, it is sufficient that the condition "one week or two weeks of continuous administration followed by one week of drug holiday" is satisfied in the administration period before the drug holiday of the first period, the administration period between the two drug holiday periods, and the administration period after the drug holiday of the second period. In another embodiment of the administration schedule having two or more drug holidays, it is sufficient to satisfy the condition of "1 week or 2 weeks of continuous administration followed by 1 week of rest period" in the administration period before the first drug holiday, the administration period between two adjacent drug holidays, and the administration period after the last drug holiday. The drug holiday is not particularly limited and can be suitably set according to the patient's condition, etc. For example, the drug holiday can be within the range of 1 day to 35 days. Alternatively, the drug holiday can be within the range of 1 to 12 months.

[0056] In addition, the administration schedule of the immune checkpoint molecule modulator is not particularly limited, so long as it is administered at regular intervals. In one embodiment, the immune checkpoint molecule modulator is administered at intervals of 1 to 3 weeks.

[0057] Nivolumab is preferably administered on a two-week or three-week administration schedule.

[0058] Pembrolizumab, atezolizumab, or ipilimumab are preferably administered on a dosing schedule at 3 week intervals.

[0059] Avelumab or durvalumab is preferably administered on a dosing schedule every two weeks.

[0060] The number of times the antitumor agent of the present disclosure is administered per day is selected appropriately depending on the type of cancer, stage of the disease, etc.

[0061] The number of times per day of administration of compound A or a salt thereof is preferably 1 or 2 times, more preferably 1 time. The number of times per day of administration of nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, or ipilimumab is preferably 1 time.

[0062] The order of administration of compound A or a salt thereof and the immune checkpoint molecule modulator of the present disclosure can be appropriately selected depending on the type of cancer, stage of the disease, etc., and these agents may be administered in any order, or may be administered in parallel when used in combination.

[0063] "Concomitant use" refers to the use of another drug in a subject undergoing treatment with a drug.

[0064] Here, when compound A or a salt thereof and the immune checkpoint molecule modulator are not administered in parallel, the administration interval between the two agents can be appropriately selected as long as the antitumor effect is enhanced, and is preferably 1 to 14 days, more preferably 1 to 7 days, even more preferably 1 to 5 days, and particularly preferably 1 to 3 days.

[0065] In the present disclosure, the target tumor is not particularly limited as long as the antitumor effect is enhanced, and is preferably a tumor for which compound A or a salt thereof exhibits an antitumor effect, more preferably a malignant tumor in which LSD1 is involved.

[0066] The type of malignant tumor to be treated by Compound A or its salt is not particularly limited. For example, glandular tumor, carcinoid tumor, undifferentiated carcinoma, angiosarcoma, adenocarcinoma, gastrointestinal cancer (e.g., colorectal cancer ("CRC") including colon cancer and rectal cancer, biliary tract cancer including gallbladder cancer and bile duct cancer, anal cancer, esophageal cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor ("GIST"), liver cancer, duodenal cancer, small intestinal cancer), lung cancer (e.g., non-small cell lung cancer ("NSCLC"), squamous cell lung cancer, large cell lung cancer, small cell lung cancer, invasive mucinous adenocarcinoma, mesothelioma, and other lung cancers such as bronchial tumors and pleuropulmonary blastoma), urological cancers (e.g., kidney cancer, transitional cell carcinoma of the kidney ("TCC"), TCC of the renal pelvis and ureter ("PDQ"), bladder cancer, urethral cancer, prostate cancer), head and neck cancers (e.g., eye cancer, retinoblastoma, intraocular melanoma, hypopharyngeal cancer, pharyngeal cancer, laryngeal cancer, laryngeal papillomatosis, metastatic squamous cell carcinoma of occult primary, paranasal sinus squamous cell carcinoma (SNSCC), oral cavity, lip, pharyngeal, oropharyngeal, aesthesioneuroblastoma, nasal and paranasal sinus, nasopharyngeal, salivary gland), endocrine cancers (e.g., thyroid cancer, parathyroid cancer, multiple endocrine neoplasia syndrome, thymoma and thymic carcinoma, pancreatic cancer such as pancreatic ductal adenocarcinoma ("PDAC"), pancreatic neuroendocrine tumors, and islet cell tumors), breast cancers (e.g., ductal carcinoma in situ ("DCIS"), lobular carcinoma in situ ("LCIS"), triple negative breast cancer, inflammatory breast cancer), male and female reproductive tract cancers (e.g., cervical cancer, ovarian cancer, endometrial cancer, uterine sarcoma, uterine cancer, vaginal cancer, vulvar cancer, gestational trophoblastic neoplasia ("GTD"), extracranial germ cell tumors, extracranial germ cell tumors, germ cell tumors, testicular cancer, penile cancer), brain and nervous system cancers (e.g., astrocytoma, brain stem glioma, brain tumor, glioblastoma (GBM), craniopharyngioma, central nervous system ("CNS") cancer, chordoma, ependymoma, embryonal tumor, neuroblastoma, Paraganglioma, atypical teratoma, oligodendrocytoma, oligodendroglioma, anaplastic oligodendrocytoma, ganglioglioma, central neurocytoma, medulloblastoma, embryonal tumor, meningioma, schwannoma, GH-secreting pituitary adenoma, PRL-secreting pituitary adenoma, ACTH-secreting pituitary adenoma, nonfunctioning pituitary adenoma, hemangioblastoma, acanthoma), skin cancer (e.g., basal cell carcinoma ("BCC"), squamous cell carcinoma ("SCC"), Merkel cell carcinoma, melanoma), tissue and cancer of the bone (e.g., soft tissue sarcoma, rhabdomyosarcoma, fibrous histiocytoma of bone, Ewing's sarcoma, malignant fibrous histiocytoma of bone ("MFH"), osteosarcoma, chondrosarcoma), cardiovascular cancer (e.g., cardiac cancer, cardiac tumors), appendix cancer, childhood and adolescent cancer (e.g., pediatric adrenocortical carcinoma, midline carcinoma, hepatocellular carcinoma (HCC), hepatoblastoma, Wilms' tumor), viral cancer (e.g., HHV-8-related cancer (Kaposi's sarcoma), HIV / AIDS-related cancer).

[0067] Tumors suitable for treatment of the present disclosure include, but are not limited to, hematological and plasma cell malignancies (e.g., cancers affecting the blood, bone marrow, and / or lymph nodes), such as multiple myeloma, leukemias and lymphomas, myelodysplastic syndromes, and myeloproliferative disorders. Leukemias include, but are not limited to, acute lymphoblastic leukemia ("ALL"), acute myeloid myeloid leukemia ("AML"), chronic lymphocytic leukemia ("CLL"), chronic myelogenous leukemia ("CML"), acute monocytic leukemia ("AMoL"), hairy cell leukemia, and / or other leukemias. Lymphomas include, but are not limited to, Hodgkin's lymphoma and non-Hodgkin's lymphoma ("NHL"). In some embodiments, the NHL is a B-cell lymphoma and / or a T-cell lymphoma. In some embodiments, the NHL is, but is not limited to, diffuse large B-cell lymphoma ("DLBCL"), small lymphocytic lymphoma ("SLL"), chronic lymphocytic leukemia ("CLL"), mantle cell lymphoma ("MCL"), Burkitt's lymphoma, cutaneous T-cell lymphoma including mycosis fungoides and Sézary syndrome, AIDS-related lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia ("WM")), primary central nervous system lymphoma, central nervous system malignant lymphoma, and / or other lymphomas.

[0068] More preferably, examples of the cancer include lung cancer (non-small cell lung cancer, small cell lung cancer, etc.) and leukemia. Further preferably, examples of the cancer include small cell lung cancer (SCLC) and acute myeloid leukemia (AML).

[0069] As shown in the Examples below, compound A or a salt thereof has an immunostimulatory effect. In this specification, the term "immunostimulatory effect" means an effect of activating immune cells such as cytotoxic T cells and macrophages, and / or an effect of inhibiting the suppression of immune responses by regulatory T cells, myeloid-derived suppressor cells (MDSC), and the like. In particular, compound A or a salt thereof has an effect of increasing cytotoxic T cells, and / or an effect of inhibiting the suppression of immune responses by granulocytic myeloid-derived suppressor cells (gMDSC).

[0070] In the present disclosure, gMDSCs can be identified by markers conventionally known to those skilled in the art. Examples of markers include CD33 + CD11b + HLA-DR - CD15 + CD14 - , CD33 + CD11b + HLA-DR low CD15 + CD14 - , CD33 + CD11b + Lin - CD15 + CD14 - , CD33 + CD11b + HLA-DR - Lin - CD15 + CD14 - , CD33 + CD11b + HLA-DR low Lin - CD15 + CD14 - Examples include:

[0071] In the present disclosure, the active ingredients, compound A or a salt thereof and the immune checkpoint molecule modulator, may be formulated in multiple dosage forms according to the dosage form or administration schedule of the active ingredients, or may be integrated and formulated into one dosage form (i.e., formulated as a combined preparation). In addition, these preparations may be manufactured and sold in one package suitable for combined administration, or may be manufactured and sold in separate packages.

[0072] In the present disclosure, the dosage form of the antitumor agent is not particularly limited and can be appropriately selected according to the purpose of treatment. Examples include oral agents (tablets, coated tablets, powders, granules, capsules, solutions, etc.), injections, suppositories, patches, ointments, etc.

[0073] In the case of Compound A or a salt thereof, oral administration is preferred.

[0074] In the case of anti-PD-1 antibody, anti-PD-L1 antibody, or anti-CTLA-4 antibody, the above-mentioned dosage forms are used, and injections are preferred.

[0075] For both compound A or its salt and immune checkpoint molecule regulator, the antitumor agent of the present disclosure can be prepared by a known method using one or more medicament-acceptable carriers according to its dosage form. Examples of carriers include various carriers commonly used in general pharmaceutical agents, such as excipients, binders, disintegrants, lubricants, diluents, solubilizers, suspending agents, tonics, pH adjusters, buffers, stabilizers, colorants, flavor improvers, and odor improvers.

[0076] According to the antitumor agent of the present disclosure, it is possible to perform cancer treatment with high antitumor effect while suppressing the occurrence of side effects. In some embodiments, the high antitumor effect includes tumor growth retardation effect and / or tumor shrinkage effect. Therefore, when the antitumor agent of the present disclosure is administered to a cancer patient, the life span of the patient can be extended.

[0077] The present disclosure also relates to an antitumor effect enhancer for enhancing the antitumor effect of an immune checkpoint molecule regulator in a cancer patient, the antitumor effect enhancer comprising compound A or a salt thereof as an active ingredient. The antitumor effect enhancer of the present disclosure has the same formulation as the above-mentioned antitumor agent.

[0078] The present disclosure also relates to an antitumor effect enhancer for enhancing the antitumor effect of compound A or a salt thereof on cancer patients, the antitumor effect enhancer comprising an immune checkpoint molecule regulator as an active ingredient. The antitumor effect enhancer of the present disclosure has the same formulation as the above-mentioned antitumor agent.

[0079] The present disclosure also relates to an antitumor agent for treating a cancer patient to whom an immune checkpoint molecule modulator has been administered, the antitumor agent comprising compound A or a salt thereof. The antitumor agent has the above-mentioned formulation form.

[0080] The present disclosure also relates to an antitumor agent for treating a cancer patient administered with compound A or a salt thereof, the antitumor agent comprising an immune checkpoint molecule modulator. The antitumor agent has the above-mentioned formulation.

[0081] "Treatment" includes postoperative adjuvant chemotherapy, which is performed after tumor removal surgery to prevent recurrence, and neoadjuvant chemotherapy, which is performed before tumor removal surgery.

[0082] The present disclosure also relates to an antitumor agent containing compound A or a salt thereof, which is used in combination with an immune checkpoint molecule regulator for cancer patients. The antitumor agent has the above-mentioned formulation.

[0083] The present disclosure also relates to an antitumor agent comprising an immune checkpoint molecule regulator, which is used in combination with an antitumor agent comprising compound A or a salt thereof for cancer patients. The antitumor agent has the above-mentioned formulation form.

[0084] The present disclosure also relates to a kit formulation comprising: an antitumor agent containing compound A or a salt thereof; and instructions for administering compound A or a salt thereof in combination with an immune checkpoint molecule modulator to a cancer patient.

[0085] Here, the "instructions" are not particularly limited as long as the above-mentioned dosage is specified. The instructions may be legally binding or not, but it is preferable that the above-mentioned dosage is recommended. Examples of the instructions include a package insert and a pamphlet. The kit preparation including the instructions may be one in which the instructions are printed or attached to the package of the kit preparation, or one in which the instructions are enclosed in the package of the kit preparation together with the antitumor agent.

[0086] The present disclosure may be used in combination with one or more anti-cancer agents other than the anti-tumor agents described above. Such anti-cancer agents include, for example, chemotherapeutic agents (e.g., cytotoxic agents), immunotherapeutic agents, hormonal and anti-hormonal agents, targeted therapeutic agents, and anti-angiogenic agents. Many anti-cancer agents fall into at least one of the above categories. Although certain anti-cancer agents are categorized herein into certain groups or subgroups, many of these agents can also be categorized into one or more other groups or subgroups, as is known in the art. Anticancer agents include, but are not limited to, chemotherapeutic agents, mitotic inhibitors, plant alkaloids, alkylating agents, metabolic antagonists, platinum analogs, enzymes, topoisomerase inhibitors, retinoids, aziridines, antibiotics, hormones, antihormones, antiestrogens, antiandrogens, antiadrenal, androgens, targeted therapeutic agents, immunotherapeutic agents, biological response modifiers, cytokine inhibitors, tumor vaccines, monoclonal antibodies, colony stimulating factors, anti-LAG1 agents, and anti-OX40 agents.

[0087] Non-limiting examples of chemotherapeutic agents include antimitotics, plant alkaloids, alkylating agents, antimetabolites, platinum analogs, enzymes, topoisomerase inhibitors, retinoids, aziridines, and antibiotics.

[0088] Non-limiting examples of mitotic inhibitors and plant alkaloids include taxanes such as cabazitaxel, docetaxel, larotaxel, ortataxel, paclitaxel, and tesetaxel; demecolcine; epothilone; eribulin; etoposide (VP-16); etoposide phosphate; navelbine; noscapine; teniposide; thaliblastine; vinblastine; vincristine; vindesine; vinflunine; vinorumine.

[0089] Non-limiting examples of alkylating agents include chlorambucil, chlornaphazine, colofosfamide, cytophosphan, estramustine, ifosfamide, mannomustine, mechlorethamine, macrochlorothamine oxide hydrochloride, melphalan, nobembicine, fenestarine, prednimustine, tris(2-chloroethyl)amine, trofosfamide, nitrogen mustards such as uracil mustard; alkyl sulfonates such as busulfan, improsulfan, and pivosulfan; carmustine, chlorozotocin, fotemustine, and lomustine. , nitrosoureas such as nimustine, ranimustine, streptozotocin, TA-07; ethylenimines and methylmelamines such as altretamine, thiotepa, triethylenemelamine, triethylenethiophosphaolamide, triethylenephosphaolamide, trimethylolomelanin; ambamustine; bendamustine; dacarbazine; cyclophosphamide; etoglucide; irofulven; mafosfamide; mitobalonitol; mitractol; picobroman; procarbazine; temozolomide; treosulfan; and triazicon.

[0090] Non-limiting examples of antimetabolites include folic acid analogs such as aminopterin, denopterin, edatrexate, methotrexate, pteropterin, raltitrexate, and trimetrexate; purine analogs such as 6-mercaptopurine, 6-thioguanine, fludarabine, forodesine, thiamiprine, and thioguanine; 5-fluorouracil (5-FU), tegafur / gimeracil / oteracil potassium, tegafur / uracil, trifluridine, trifluridine / tipiracil hydrochloride, 6-azauridine, ancitabine, and azacylate. Pyrimidine analogs such as tabine, capecitabine, carmofur, cytarabine, decitabine, dideoxyuridine, doxifuridine, doxifluridine, enokitabine, floxuridine, galocitabine, gemcitabine, and sapacitabine; 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; broxuridine; cladribine; cyclophosphamide; cytarabine; emitefur; hydroxyurea; mercaptopurine; nelarabine; pemetrexed; pentostatin; tegafur; and troxacitabine.

[0091] Non-limiting examples of platinum analogs include carboplatin, cisplatin, dicycloplatin, heptaplatin, lobaplatin, nedaplatin, oxaliplatin, satraplatin, triplatin tetranitrate.

[0092] Non-limiting examples of enzymes include asparaginase, pegaspagase.

[0093] Non-limiting examples of topoisomerase inhibitors include acridine carboxamide, amonafide, ansacrine, belotecan, elliptinium acetate, exatecan, indolocarbazole, irinotecan, lurtotecan, mitocoxanthone, razoxane, rubitecan, SN-38, sobuzoxane, topotecan.

[0094] Non-limiting examples of retinoids include alitretinoin, bexarotene, fenretinide, isotretinoin, ryazole, RII retinamide, tretinoin.

[0095] Non-limiting examples of aziridines include benzodopa, carboquone, metuledopa, and uredopa.

[0096] Non-limiting examples of antibiotics include intercalate antibiotics; anthracenediones; anthracycline antibiotics such as aclarubicin, amrubicin, daunomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, nogamicin, pirarubicin, and barbicin; 6-diazo-5-oxo-L-norleucine; aclacinomycin; actinomycin; autramycin; azaserine; bleomycin; cactinomycin; caliciamycin; carabimycin; carzinophycin; carzinophycin; Examples of anti-inflammatory drugs include: linoleic acid; chromomycin; dactinomycin; detorubicin; esorubicin; esperamicin; geldanamycin; marceromycin; mitomycins; mitomycin C; mycophenolic acid; olivomycin; novantromycin; peplomycin; porfiromycin; pothiromycin; puromycin; chelamycin; rebeccamycin; rodorubicin; streptonigrin; streptozocin; tanespimycin; tubercidin; ubenimex; zinostatin; zinostatin styramer; and zorbidine.

[0097] Non-limiting examples of hormones and anti-hormones include anti-androgens such as abiraterone, apalutamide, bicalutamide, darolutamide, enzalutamide, flutamide, goserelin, leuprolide, and nilutamide; 4-hydroxytamoxifen, aromatase-inhibiting 4(5)-imidazole, EM-800, fosfestrol, fulvestrant, keoxifene, LY117018, onapristone, raloxifene, tamoxifen, toremifene, and trioxyphene. Examples of such antiestrogens include anti-estrogen such as aminoglutethimide, dexaminoglutethimide, mitotane, and trilostane; anti-adrenergic agents such as calcosterone, dromostanolone propionate, epithiostanol, mepitiostane, and testolactone; abarelix; anastrozole; cetrorelix; deslorelin; exemestane; fadrozole; finasteride; formistane; histrelin (RL0903); human chorionic gonadotropin; lanreotide; LDI 200 (Milk House); letrozole; leuprorelin; mifepristone; nafarelin; nafoxidine; osaterone; prednisone; thyrotropin alpha; and tryptoarin.

[0098] Non-limiting examples of immunotherapeutic agents (ie, immunotherapies) include biological response modifiers, cytokine inhibitors, tumor vaccines, monoclonal antibodies, colony stimulating factors, and immunomodulatory agents.

[0099] Non-limiting examples of biological response modifiers including cytokine inhibitors (cytokines) such as interferons and interleukins include interferon alpha / interferon alpha, such as interferon alpha-2, interferon alpha-2a, interferon alpha-2b, interferon alpha-nl, interferon alpha-n3, interferon alfacon-1, pegylated interferon alpha-2a, pegylated interferon alpha-2b, leukocyte alpha interferon; interferon beta, such as interferon beta-1a, interferon beta-1b; interferon gamma, such as natural interferon gamma-1a, interferon gamma-1b; aldesleukin; interferon 1 beta; interferon 2; oprelvekin; sonarmin; tasonarmin; and virizin.

[0100] Non-limiting examples of tumor vaccines include APC8015, AVICINE, bladder cancer vaccine, cancer vaccine (Biomira), gastrin 17 immunogen, Maruyama vaccine, melanoma lysate vaccine, melanoma oncolyzer vaccine (New York Medical College), melanoma vaccine (New York University), melanoma vaccine (Sloan Kettering Institute), TICE® BCG (Bacillus Calmette-Guerin), viral melanoma cytolytic vaccine (Royal Newcastle Hospital).

[0101] Non-limiting examples of monoclonal antibodies include abagovomab, adecatumumab, aflibercept, alemtuzumab, blinatumomab, brentuximab vedotin, CA125MAb (Biomira), cancer MAb (Nihon Iyaku Kaihatsu), daclitumab, daltuzumab, denozumab, etrecolomab, gemtumab zogamicin, HER-2 and Fc MAb (Medarex), ibritumomab tiuxetan, idiotype 105AD7 MAb (CRC Technology), idiotype CEA MAb (Trilex), lintuzumab, LYM-1-iodine 131 MAb (Techniclone), mitumomab, moxetumomab, octamumab, polymorphous epithelial mucin yttrium 90 These include MAbs (antisomas), ranibizumab, rituximab, veltuzumab, and trastuzumab.

[0102] Non-limiting examples of colony stimulating factors include darbepoetin alfa, epoetin alfa, epoetin beta, filgrastim, granulocyte macrophage colony stimulating factor, lenograstim, relidistim, millimostim, molgramostim, nartograstim, pegfilgrastim, and sargramostim.

[0103] Non-limiting examples of other immunotherapeutic agents include BiTEs, CAR-T cells, GITR agonists, imiquimod, immunomodulatory imides (ImiDs), mismatched double-stranded RNA (Ampligen), resiquimod, SRL172, thymalfasin.

[0104] Targeted therapeutic agents include, for example, monoclonal antibodies and small molecule drugs. Non-limiting examples of targeted therapeutic agents include signal transduction inhibitors, growth factor inhibitors, tyrosine kinase inhibitors, EGFR inhibitors, HER2 inhibitors, histone deacetylase (HDAC) inhibitors, proteasome inhibitors, cell cycle inhibitors, angiogenesis inhibitors, matrix metalloproteinase (MMP) inhibitors, hepatocyte growth factor inhibitors, TOR inhibitors, KDR inhibitors, VEGF inhibitors, fibroblast growth factor (FGF) inhibitors, RAF inhibitors, MEK inhibitors, ERK inhibitors, PI3K inhibitors, AKT inhibitors, MCL-1 inhibitors, BCL-2 inhibitors, SHP2 inhibitors, BRAF inhibitors, RAS inhibitors, gene expression regulators, autophagy inhibitors, apoptosis inducers, antiproliferative agents, and glycolysis inhibitors.

[0105] Non-limiting examples of signal transduction inhibitors include tyrosine kinase inhibitors, multikinase inhibitors, anlotinib, avapritinib, axitinib, dasatinib, dovitinib, imatinib, lenvatinib, lonidamine, nilotinib, nintedanib, pazpanib, pegvisoman, ponatinib, vandetanib, EGFR and / or HER2 inhibitors.

[0106] Non-limiting examples of EGFR inhibitors include small molecule antagonists of EGFR such as afatinib, brigatinib, erlotinib, gefitinib, lapatinib, neratinib, dacomitinib, vandetanib, osimertinib; antibody-based EGFR inhibitors, including any anti-EGFR antibody or antibody fragment that can partially or completely block EGFR activation by its natural ligand. Examples of antibody-based EGFR inhibitors include EGFR inhibitors described in Modjtahedi, H., et al., 1993, Br. J. Cancer 67:247-253, Teramoto, T., et al., 1996, Cancer 77:639-645, Goldstein et al., 1995, Clin. Cancer Res. 1:1311-1318, Huang, SM, et al., 1999, Cancer Res. 15:59(8):1935-40, and Yang, X., et al., 1999, Cancer Res. 59:1236-1243; monoclonal antibody Mab E7.6.3 (Yang, 1999 supra); Mab C225 (ATCC Accession No. HB-8508), or an antibody or antibody fragment having the binding specificity thereof; Specific antisense nucleotides or siRNAs; afatinib, cetuximab, matuzumab, necitumab, nimotuzumab, panitumumab, zalutumumab.

[0107] Non-limiting examples of HER2 inhibitors include HER2 tyrosine kinase inhibitors such as afatinib, lapatinib, neratinib, and tucatinib; anti-HER2 antibodies or drug conjugates thereof such as trastuzumab, trastuzumab emtansine (T-DM1), pertuzumab, margetuximab, trastuzumab deruxtecan (DS-8201a), and trastuzumab ducalmazine.

[0108] Non-limiting examples of histone deacetylase (HDAC) inhibitors include belinostat, panobinostat, romidepsin, and vorinostat.

[0109] Non-limiting examples of proteasome inhibitors include bortezomib, carfilzomib, ixazomib, marizomib (salinosporamide a), and oprozomib.

[0110] Non-limiting examples of cell cycle inhibitors, including CDK inhibitors, include abemaciclib, alvocidib, palbociclib, and ribociclib.

[0111] Non-limiting examples of anti-angiogenic agents (or angiogenesis inhibitors) include matrix metalloproteinase (MMP) inhibitors; VEGF inhibitors; EGFR inhibitors; TOR inhibitors such as everolimus and temsirolimus; PDGFR kinase inhibitors such as crenolanib; HIF-1α inhibitors such as PX478; HIF-2α inhibitors such as velzutifan and those described in WO2015 / 035223; fibroblast growth factor (FGF) or FGFR inhibitors such as B-FGF and RG13577; and hepatocyte growth factor inhibitors. ; KDR inhibitors; anti-Ang1 and anti-Ang2 agents; anti-Tie2 kinase inhibitors; Tek antagonists (U.S. Patent Application Publication No. 2003 / 0162712; U.S. Patent No. 6,413,932); anti-TWEAK agents (U.S. Patent Application Publication No. 6,727,225); ADAM distegrin domains that antagonize integrin binding to ligands (U.S. Patent Application Publication No. 2002 / 0042368); anti-eferector and / or anti-epherin antibodies or antigen binding regions (U.S. Patent Nos. 5,981,245; 5,728,813; 5,969,110; 6,596,852; 6,232,447; 6,057,124); anti-PDGF-BB antagonists, and antibodies or antigen binding regions that specifically bind to PDGF-BB ligands.

[0112] Non-limiting examples of matrix metalloprotease (MMP) inhibitors include MMP-2 (matrix metalloprotease 2) inhibitors, MMP-9 (matrix metalloprotease 9) inhibitors, prinomastat, RO32-3555, RS13-0830. Examples of useful matrix metalloproteinase inhibitors are described, for example, in WO 96 / 33172, WO 96 / 27583, EP 1004578, WO 98 / 07697, WO 98 / 03516, WO 98 / 34918, WO 98 / 34915, WO 98 / 33768, WO 98 / 30566, EP 0606046, EP 0931788, WO 90 / 05719, WO 99 / 52910, WO 99 / 52889, WO 99 / 29667, WO 1999 / 007675, and the like. , EP 1786785, EP 1181017, US 2009 / 0012085, US 5,863,949, US 5,861,510, and EP 0780386. Preferably, the MMP-2 and MMP-9 inhibitor has little or no activity inhibiting MMP-1. More preferably, it selectively inhibits MMP-2 and / or MMP-9 relative to other matrix-metalloproteinases (i.e., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).

[0113] Non-limiting examples of VEGF and VEGFR inhibitors include bevacizumab, cediranib, CEP7055, CP547632, KRN633, orantinib, pazopanib, pegaptanib, pegaptanib octasodium, semaxanib, sorafenib, sunitinib, VEGF antagonist (Borean, Denmark), VEGF-TRAP®.

[0114] Non-limiting examples of other antiangiogenic agents include 2-methoxyestradiol, AE 941, alemtuzumab, α-D148Mab (Amgen, USA), alphastatin, anecortabeacetate, angiocidin, angiogenesis inhibitor (SUGEN, USA), angiostatin, anti-Vn Mab (Crucell, Netherlands), atiprimod, axitinib, AZD9935, BAY RES 2690 (Bayer, Germany), BC1 (Genoa Institute of Cancer Research, Italy), beloraneve, benefin (Lane Labs, USA), cabozantinib, CDP791 (Celltech Group, UK), chondroitinase AC, cilengitide, combretastatin A4 prodrug, CP564959 (OSI, USA),CV247, CYC381 (Harvard University, USA), E7820, EHT0101, endostatin, enzastaurin hydrochloride, ER-68203-00 (IVAX, USA), fibrinogen E fragment, Flk-1 (ImClone Systems, USA), some forms of FLT1 (VEGFR1), FR-111142, GCS-100, GW2286 (GlaxoSmithKline, UK), IL-8, Ilomastat, IM-862, irsogladine, KM-2550 (Kyowa Hakko, Japan), lenalidomide, lenvatinib, MAb α5β3 integrin second generation (Applied Molecular Evolution, USA, and MedImmune, USA), MAb VEGF (Xenova, UK), marimastat, maspin (Sosei, Japan), metastatin, motuporamine C, M-PGA, ombrabulin, OXI 4503, PI 88, platelet factor 4, PPI2458, ramucirumab, rBPI 21 and BPI-derived angiogenesis (XOMA, USA), regorafenib, SC-236, SD-7784 (Pfizer, USA), SDX 103 (University of California, San Diego, USA), SG292 (Telios, USA), SU-0879 (Pfizer, USA), TAN-1120, TBC-1635, tesevatinib, tetrathiomolybdate, thalidomide, thrombospondin 1 inhibitor, tie 2 ligand (Regeneron, USA), tissue factor pathway inhibitor (EntreMed, USA), tumor necrosis factor-α inhibitor, tumstatin, TZ 93, urokinase plasminogen activator inhibitors, vadimezan, vandetanib, vasostatin, vatalanib, VE-cadherin 2 antagonists, xanthorizol, XL 784 (Exelixis, USA), divalflibercept, and ZD6126.

[0115] Anticancer drugs that may be used in combination with compound A may be active agents that inhibit the RAS-RAF-ERK signaling pathway or the PI3K-ACT-TOR signaling pathway. Non-limiting examples of such anticancer drugs include RAF inhibitors, EGFR inhibitors, MEK inhibitors, ERK inhibitors, PI3K inhibitors, AKT inhibitors, TOR inhibitors, MCL-1 inhibitors, BCL-2 inhibitors, SHP2 inhibitors, proteasome inhibitors, or immunotherapies such as monoclonal antibodies, immunomodulatory imids (IMiDs), anti-LAGl, anti-OX40 agents, GITR agonists, CAR-T cells, and BiTEs.

[0116] Non-limiting examples of RAF inhibitors include dabrafenib, encorafenib, regorafenib, sorafenib, and vemurafenib.

[0117] Non-limiting examples of MEK inhibitors include binimetinib, CI-1040, cobimetinib, PD318088, PD325901, PD334581, PD98059, rifametinib, selumetinib, and trametinib.

[0118] Non-limiting examples of ERK inhibitors include LY3214996, LTT462, MK-8353, SCH772984, ravoxatinib, urixatinib, and ASTX029.

[0119] Non-limiting examples of PI3K inhibitors include 17-hydroxywortmannin analogs (e.g., WO 06 / 044453); AEZS-136; alpelisib; AS-252424; buparisib; CAL263; copanlisib; CUDC-907; dactolisib (WO 06 / 122806); demethoxyviridin; duvelisib; GNE-477; GSK1059615; IC87114; idelalisib; INK1117; LY294002; Palomid 529; paxalisib; perifosine; PI-103; PI-103 hydrochloride; pictilisib (e.g., WO 09 / 036,082; WO 09 / 055,730); PIK90; PWT33597; SF1126; sonolisib; TGI00-115; TGX-221; XL-147; XL-765; wortmannin; taselisib (GDC-0032); ZSTK474.

[0120] Non-limiting examples of AKT inhibitors include Akt-1-1 (inhibits Aktl) (Barnett et al. (2005) Biochem. J., 385 (Pt. 2), 399-408); Akt-1-1,2 (Barnett et al. (2005) Biochem. J. 385 (Pt. 2), 399-408); API-59CJ-Ome (e.g., Jin et al. (2004) Br. J. Cancer 91, 1808-12); 1-H-imidaso[4,5-c]pyridinyl compounds (e.g., WO 05011700); indole-3-carbinol and its derivatives (e.g., U.S. Pat. No. 6,656,963; Sarkar and Li (2004) J Nutr. 134 (12 Suppl), 3493S-3498S); perifosine, Dasmahapatra et al. (2004) Clin. Cancer Res. 10(15), 5242-52, 2004; phosphatidylinositol ether lipid analogues (e.g., Gills and Dennis (2004) Expert. Opin. Investig. Drugs 13, 787-97); triciribine (Yang et al. (2004) Cancer Res. 64, 4394-9; trans-3-amino-1-methyl-3-[4-(3-phenyl-5H-imidazo[1,2-c]pyrido[3,4-e][1,3]oxazin-2-yl)phenyl]-cyclobutanol hydrochloride (WO 2012 / 137870); Afuresertiv; Capivasertiv; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2, 4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one (MK2206) and its pharmaceutically acceptable salts; AZD5363; trans-3-amino-1-methyl-3-(4-(3-phenyl-5H-imidazo[1,2-c]pyrido[3,4-e][1,3]oxazin-2-yl)phenyl)cyclobutanol (TAS117) and its pharmaceutically acceptable salts; and pataxertiv.

[0121] Non-limiting examples of TOR inhibitors include deforolimus; ATP-competitive TORC1 / TORC2 inhibitors, including PI-103, PP242, PP30, and torin 1; TOR inhibitors of the FKBP12 enhancer; rapamycin and its derivatives, such as temsirolimus, everolimus, and WO 9409010; rapalogs disclosed in WO 98 / 02441 and WO 01 / 14387, e.g., AP23573, AP23464, AP23841; 40-(2-hydroxyethyl)rapamycin, 40-[3-hydroxy(hydroxymethyl)methylpropanoic acid]-rapamycin; 40-epi-(tetrazolyl)-rapamycin (also known as ABT578); AZD8055; 32-deoxy-3-(hydroxyethyl)rapamycin; Isin; 16-pentynyloxy-32(S)-dihydrapamycin and other derivatives disclosed in WO 05 / 005434; U.S. Pat. No. 5,258,389, WO 94 / 090101, WO 92 / 05179, U.S. Pat. No. 5,118,677, U.S. Pat. No. 5,118,678, U.S. Pat. No. 5,100,883, U.S. Pat. No. 5,151,413, U.S. Pat. No. 5,120,842, WO 93 / 111130, WO 94 / 021336, WO 94 / 02485, WO 95 / 14023, WO 94 / 0213, WO 95 / 16691, WO 96 / 41807, WO 96 / 41807, U.S. Pat. No. 5,256,790; and phosphorus-containing rapamycin derivatives (e.g., WO 05 / 016252).

[0122] Non-limiting examples of MCL-1 inhibitors include AMG-176, MIK665, S63845.

[0123] Non-limiting examples of SHP2 inhibitors include JAB-3068, RMC-4630, TNO155, SHP-099, RMC-4550, and the SHP2 inhibitors described in WO 2019 / 167000, WO 2020 / 022323, and WO 2021 / 033153.

[0124] Non-limiting examples of RAS inhibitors include AMG510 (sotorasib), MRTX849, LY3499446, JNJ-74699157 (ARS-3248), ARS-1620, ARS-853, RM-007, RM-008.

[0125] Additional non-limiting anti-cancer agents suitable for use include, for example, 2-ethylhydrazide, 2,2',2"-trichlorotriethylamine, ABVD, aceglatone, acemannan, aldophosphamide glycosides, alpharadin, amifostine, aminolevulinic acid, anagrelide, ANCER, ancestim, anti-CD22 immunotoxin, antitumor herb, apaziquone, aruglavin, arsenic trioxide, azathioprine, BAM002 (Nobelos), bcl-2 (Genta), bestravsil, biricoder, bisantrene, bromocriptine, brostallicin, and bromide. Liostatin, buthionine sulfoximine, kalinculin, cell cycle non-specific anticancer agents, cermoleukin, clodronate, clotrimazole, cytarabine ocfosfate, DA3030 (Toa), defofamine, denirukine diftox, dexrazoxane, diaziquone, dichloroacetic acid, dilazep, discodermolide, docosanol, doxelsiferol, edelfosine, efurnithine, EL532 (Elan), elcomycin, elsamitrusen, eniluracil, etanidazole, exisulind, feruginol Folic acid supplements such as florinic acid, gatitosine, gallium nitrate, gimeracil / oteracil / tegafur combination (S-1), glycopin, histamine dihydrochloride, HIT diclofenac, HLA-B7 gene therapy (Vical), human fetal alpha-fetoprotein, ibandronate, ibandronic acid, ICE chemotherapy regimen, imexon, iobengen, IT-101 (CRLX101), lanicida, LC9018 (Yakult), leflunomide, lentinan, levamisole + fluorouracil, lovastatin, lucanton, masoprocol, melalsporol, melamine Toclopramide, Miltefosine, Miprokifen, Mitobazone, Mitromid, Mopidamol, Motexafin Gadolinium, MX6 (Galderma), Naloxone + Pentazocine, Nitracrine, Noratrequid, NSC631570 Octreotide (Ukrain), Olaparib, P-30 protein, PAC-1, Palifermin, Pamidronate, Pamidronic acid, Pentosan polysulfate sodium, Fenamet, Piquibanil, Pixantrone, Platinum, Podophyllic acid, Porfirma sodium, PSK (Polysaccharide-K),Rabbit antithymocyte polyclonal antibody, rasbribodyment, retinoic acid, rhenium Re186 etidronate, romurtide, samarium (153Sm) lexidronam, sizofiran, sodium phenylacetate, sparhogic acid, spiroglumanium, strontium-89 chloride, suramin, swanonin, tarapofin, tariquidar, tazarotene, tegafur-uracil, temoporfin, tenuazonic acid, tetrachlorodecaoxide, thrombopoietin, tin ethyl etiopurine, tirapazamine, TLC ELL-12, tositumomab-iodine 131, trifluridine-tipiracil combination, troponin I (Harvard University, USA), urethane, valspode, valteporfin, zoledronic acid, and zoscudar. EXAMPLES

[0126] Hereinafter, the present disclosure will be further described with reference to examples, but the present disclosure is not limited thereto, and those skilled in the art can make modifications within the scope of the technical ideas described in this specification.

[0127] Example 1: Immunostimulatory effect of biphenyl compounds in a colon cancer cell transplant model

[0128] The mouse colon cancer cell line MC38 was obtained from Dr. Yoshihiro Hayakawa (Toyama University, Toyama, Japan). The MC38 cell line was cultured in RPMI1640 medium containing 10% fetal bovine serum, and then subcultured once or twice a week in an incubator at 37°C in the presence of 5% CO2.

[0129] MC38 cell suspension 1.5 x 10 6 The cells / 0.1 ml were subcutaneously transplanted into the right thorax of 6-week-old C57BL / 6JJcl mice (CLEA Japan, Inc.).

[0130] After transplantation, tumor volume (TV) was 80–230 mm 3 The tumor was allowed to grow until it reached a diameter of 10 mm. A digital caliper was used to measure the tumor diameter. The tumor diameters were measured and the TV was calculated using the following formula: TV(mm 3) = major axis (mm) × minor axis (mm) × minor axis (mm) / 2

[0131] Five mice were assigned to each group by stratified random allocation using TV as an index. The day of group allocation (n=5) was designated as day 0.

[0132] In order to adjust the hypromellose concentration to 0.5 w / v%, an appropriate amount of water for injection as specified in the Japanese Pharmacopoeia was added, and the hypromellose was completely dissolved by stirring with a stirrer to prepare a 0.5% hypromellose aqueous solution. The benzoate of compound A (the benzoate of compound A was used in the examples. Therefore, hereinafter, "compound A" refers to the benzoate of compound A) was crushed in an agate mortar, suspended in a 0.5% hypromellose aqueous solution to a predetermined concentration, and subjected to ultrasonic treatment to obtain a uniform suspension. The suspension containing compound A was orally administered once a day for 6 consecutive days at a dose of 25 mg / kg / day. The dosage was based on the free form of compound A.

[0133] Anti-mouse PD-1 antibody (anti-mPD-1Ab) was prepared by diluting anti-PD-1, CD279 (PD-1) monoclonal antibody (clone: ​​RMP1-14, Thermo Fisher Scientific) with Dulbecco's phosphate-buffered saline (Nacalai Tesque, INC) to a specified concentration immediately before administration. On the first day of administration (Day 1), this diluted solution was administered intraperitoneally at a dose of 0.05 mg / body of anti-mouse PD-1 antibody.

[0134] To detect the expression of immune-related factors, flow cytometry analysis for immunological monitoring was performed. Tumors were harvested on day 7, and tumor-infiltrating lymphocytes were prepared using a Tumor Dissociation Kit, mouse (Miltenyi Biotec). The isolated lymphocytes were then stained with the following antibodies and analyzed using a flow cytometer, FACS Verse (BD Bioscience). For staining, the following antibodies were used: CD45 monoclonal antibody (30-F11) eFluor450, eBioscience® (Thermo Fisher Scientific), Brilliant Violet 510® anti-mouse CD90.2 antibody (30-H2) (BioLegend), CD11b monoclonal antibody (M1 / 70) PE, eBioscience® (Thermo Fisher Scientific), Ly-6G antibody anti-mouse (REA526), ​​REAfinity® (Miltenyi Biotec), and CD8a monoclonal antibody (53-6.7) FITC, eBioscience® (Thermo Fisher Scientific).

[0135] The results are shown in Figures 1A and 1B.

[0136] The ratio of gMDSC (CD45 positive, CD90.2 negative, CD11b positive, Ly6G positive cells) in leukocytes (CD45 positive cells) in each group on day 7 was analyzed by Dunnett's test. The ratio of gMDSC in leukocytes was significantly lower in the compound A administration group on day 7 compared to the control group. The ratio of CD8 positive cells (CD45 positive, CD90.2 positive, CD8 positive cells) in leukocytes in each group on day 7 was analyzed by Dunnett's test. The ratio of CD8 positive cells in leukocytes in the compound A and anti-mouse PD-1 antibody combination administration group on day 7 was significantly higher than that in the control group.

[0137] From the above results, it was found that compound A exhibits immunostimulatory activity.

[0138] Example 2: Effects of biphenyl compounds in colon cancer cell transplantation models

[0139] The MC38 cell suspension was injected into the right chest of 6-week-old C57BL / 6JJcl mice (CLEA Japan) or CB17 / Icr-Prkdc[scid] / CrlCrlj (Charles River Japan) at 2.0 × 10 6 CB17 / Icr-Prkdc[scid] / CrlCrlj mice are immunodeficient mice due to a deficiency of T and B cells in the peripheral blood.

[0140] After transplantation, tumor volumes (TV) were 50–300 mm 3 The tumor was allowed to grow until it reached a diameter of 10 mm. A digital caliper was used to measure the tumor diameter. The tumor diameters were measured and the TV was calculated using the following formula: TV(mm 3 ) = major axis (mm) × minor axis (mm) × minor axis (mm) / 2

[0141] C57BL / 6JJcl mice were assigned to each group (10 mice per group) and CB17 / Icr-Prkdc[scid] / CrlCrlj mice were assigned to each group (5 mice per group) using a stratified random allocation method based on TV. The day of group allocation was designated as day 0.

[0142] Body weight was measured using an electronic balance for animals. The body weight change rate on day n (BWCn) was calculated from the body weight on day n (BWn) according to the following formula: Weight change rate BWCn(%)=(BWn-BW0) / BW0× 100

[0143] To adjust the hypromellose concentration to 0.5 w / v%, an appropriate amount of water for injection as specified in the Japanese Pharmacopoeia was added, and the hypromellose was completely dissolved by stirring with a stirrer to prepare a 0.5% hypromellose aqueous solution. The benzoate of compound A was crushed in an agate mortar, suspended in a 0.5% hypromellose aqueous solution to a specified concentration, and sonicated to obtain a uniform suspension. This suspension containing compound A was orally administered at a dose of 25 mg / kg / day once a day for 21 consecutive days. The dose was based on the free form of compound A. The results are shown in Figures 2A and 2B and Tables 1 and 2.

[0144] [Table 1]

[0145] [Table 2]

[0146] As a result of analyzing the TV of each group on day 22 using the Aspin-Welch t-test, the compound A administration group of the wild-type mouse model showed an antitumor effect at a significantly lower TV than the control group. On the other hand, the compound A administration group of the immunodeficient mouse model showed no antitumor effect compared to the control group.

[0147] Example 3: Biphenyl compounds and immunization in a colon cancer cell transplant model Checkpoint molecular regulators Combined effect of

[0148] The MC38 cell suspension was inoculated into the right chest of 6-week-old C57BL / 6JJcl mice (CLEA Japan, Inc.) at 2.0 × 10 6 The cells were subcutaneously transplanted at a concentration of 0.1 ml.

[0149] After transplantation, tumor volumes (TV) were 50–300 mm 3 The tumor was allowed to grow until it reached a diameter of 10 mm. A digital caliper was used to measure the tumor diameter. The tumor diameters were measured and the TV was calculated using the following formula: TV(mm 3) = major axis (mm) × minor axis (mm) × minor axis (mm) / 2

[0150] Ten mice were assigned to each group by stratified random allocation using TV as an index. The day of group allocation was designated as day 0.

[0151] Body weight was measured using an electronic balance for animals. The body weight change rate on day n (BWCn) was calculated from the body weight on day n (BWn) according to the following formula: Weight change rate BWCn(%)=(BWn-BW0) / BW0× 100

[0152] To adjust the hypromellose concentration to 0.5 w / v%, an appropriate amount of water for injection as specified in the Japanese Pharmacopoeia was added, and the hypromellose was completely dissolved by stirring with a stirrer to prepare a 0.5% hypromellose aqueous solution. The benzoate of compound A was crushed in an agate mortar, suspended in a 0.5% hypromellose aqueous solution to a specified concentration, and sonicated to obtain a uniform suspension. This suspension containing compound A was orally administered at a dose of 25 mg / kg / day once a day for 21 consecutive days. The dose was based on the free form of compound A.

[0153] Anti-mouse PD-1 antibody (anti-mPD-1 Ab) was prepared by diluting anti-PD-1, CD279 (PD-1) monoclonal antibody (clone: ​​RMP1-14, Bio X cell) with saline (Otsuka Pharmaceutical Factory Inc.) to a predetermined concentration immediately before administration. On the first day of administration (Day 1), this dilution was administered intraperitoneally at a dose of 0.05 mg / body of anti-mouse PD-1 antibody.

[0154] The results are shown in Figure 3 and Table 3.

[0155] [Table 3]

[0156] The TV of each group on day 22 was analyzed by Aspin-Welch t-test, and the group administered with compound A or anti-mouse PD-1 antibody alone and the group administered with compound A + anti-mouse PD-1 antibody in combination showed significantly lower TV and anti-tumor effect compared to the control group. Furthermore, the group administered with compound A + anti-mouse PD-1 antibody in combination showed significantly lower TV and higher anti-tumor effect compared to the group administered with compound A or anti-mouse PD-1 antibody alone.

[0157] The results of the average body weight change rate in the combination administration group showed no enhanced toxicity compared to the single agent administration groups administered only compound A or anti-mouse PD-1 antibody.

Claims

1. An antitumor agent for use in treating a subject having cancer, comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof, An anti-tumor agent, wherein the treatment comprises administering to a subject an immune checkpoint molecule modulator.

2. The antitumor agent according to claim 1, wherein the immune checkpoint molecule regulator is at least one selected from the group consisting of a PD-1 pathway antagonist and a CTLA-4 pathway antagonist.

3. The antitumor agent of claim 1, wherein the immune checkpoint molecule regulator is a PD-1 pathway antagonist.

4. The antitumor agent according to claim 2 or 3, wherein the PD-1 pathway antagonist is at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody.

5. The antitumor agent according to claim 2 or 3, wherein the PD-1 pathway antagonist is an anti-PD-1 antibody or an anti-PD-L1 antibody.

6. The antitumor agent according to claim 2 or 3, wherein the PD-1 pathway antagonist is an anti-PD-1 antibody.

7. The antitumor agent of claim 2, wherein the CTLA-4 pathway antagonist is an anti-CTLA-4 antibody.

8. An agent for enhancing the antitumor effect of an immune checkpoint molecule regulator, comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof as an active ingredient.

9. An antitumor agent for treating a cancer patient to whom an immune checkpoint molecule modulator has been administered, comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof.

10. An antitumor agent for treating a cancer patient to whom 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof, which comprises an immune checkpoint molecule regulator, is administered.

11. An immune checkpoint molecule modulator for use in treating a tumor in a cancer patient administered 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof.

12. A combination pharmaceutical comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof and an immune checkpoint molecule modulator for use in treating a tumor.

13. Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof for producing an antitumor agent to be administered in combination with an immune checkpoint molecule regulator.

14. Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof for producing an antitumor effect enhancer for enhancing the antitumor effect of an immune checkpoint molecule regulator.

15. Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof for the manufacture of an antitumor agent for treating a cancer patient to whom an immune checkpoint molecule modulator has been administered.

16. Use of an immune checkpoint molecule regulator for the manufacture of an antitumor agent for treating a cancer patient to which 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof has been administered.

17. Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof and an immune checkpoint molecule regulator for the manufacture of an antitumor agent.

18. A pharmaceutical composition for preventing and / or treating a tumor, comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[(2-fluoro-4-methyl-propyl)phenyl]phenyl]-2-fluorobenzonitrile or a salt thereof, and an immune checkpoint molecule regulator.